Tobacco as a possible prognostic factor in advanced renal cell carcinoma.

• DOI: 10.1200/jco.2019.37.7_suppl.665
• Publication Date: 2019-03-07T21:30:11Z
• Authors: Maria Pilar Solis...; Clara Iglesias; Alfonso Revuelta; Carmen Gonzalez M...; Lucia Juan Rodriguez; Teresa Quiñones R...; Sara Gonzalez Lolo; Jorge del Río Fer...; David Gómez; Sena Valcárcel Go...; Sara Fernandez Ar...; Carlos Alvarez-Fe...; Noemí Villanueva; Laura Faez; Esther Uriol; Emilio Esteban
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

665 Background: It is widely known the causal relationship establised between tobacco use and development of renal cancer known. Nevertheless, impact smoking on efficacy safety anti-angiogenic drugs unclear. Sunitinib a tyrosine kinase inhibitor with proven metastatic cell carcinoma (mRCC). Methods: A retrospective analysis was carried out including 194 mRCC patients (pts) who received in single Institution (Hospital Universitario Central de Asturias) high incidence this disease. The aim study to explore habit treatment response terms progression‐free survival (PFS) overall (OS). Results: Most presented clear histology (92%). Smoking status: 42% (n=82) never‐smoker, 39% (n=76) former‐smoker 19% (n=36) current‐smoker. Male predominance 78% (n=145). Median age 65 (range: 40‐84). Survival favors history use. There no significant difference PFS never‐smoker vs ever-smoker groups: median 8.13 months (95% IC: 4.75‐11.52), 12 9.97‐14.03) found respectively (p=0,086). Fewer than 10% developed grade 3 toxicity. significative improvement OS ever-smokers: 16.23 12.22‐20.25) 26.46 16.21‐36.73) (p=0.044). advantage observed any became more evident for poor prognosis cases. 5.03 0.84‐9.23) 14.03 7.81‐20.26). 6.4 2.53‐10.27) 13.33 1.14‐26.19) p > 0.05. Conclusions: In series, seems play role anti‐angiogenic agents mRCC. However, additional prospective studies well‐balanced populations are required confirm data.